- US-listed companies
- Arcadia Biosciences, Inc.
- Income statement
Arcadia Biosciences, Inc. (RKDA) Income statement
Market cap
$2.52M
P/E ratio
| 2015/12 | 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | |
| Revenue | 5 | 3 | 4 | 1 | 1 | 8 | 7 | 10 | - | - |
| Revenue growth (%) | - | - | - | |||||||
| Cost of revenue | 1 | 1 | 0 | - | - | - | 9 | 10 | - | - |
| Research & development | 9 | 9 | 7 | 6 | 7 | 8 | 4 | 2 | - | - |
| Selling, general & administrative | 11 | 12 | 11 | 12 | 14 | 16 | 23 | 18 | - | - |
| Operating margin (%) | - | - | ||||||||
| Operating expenses | 21 | 22 | 18 | 18 | 21 | 21 | 42 | 29 | - | - |
| Operating income | -16 | -19 | -14 | -17 | -19 | -13 | -36 | -19 | - | - |
| Income before tax | -18 | -20 | -16 | - | - | - | - | - | - | - |
| Pretax margin (%) | -331.2 | -614.8 | -389.5 | - | - | - | - | - | - | - |
| Provision for income taxes | 0 | 0 | 26,000 | 10,000 | 2,000 | -124,000 | 0 | 0 | - | - |
| Effective tax rate (%) | - | - | - | - | - | - | - | |||
| Net income | -18 | -20 | -16 | -13 | -29 | -5 | -15 | -15 | -14 | -7 |
| Net income margin (%) | - | - | ||||||||
| Earnings per share | - | - | - | - | - | - | - | -25.65 | - | - |
| Diluted EPS | - | - | - | - | - | - | - | -25.65 | - | - |